Cárdenas Andrés, Arroyo Vicente
Institut de Malalties Digestives i Metaboliques, University of Barcelona, Hospital Clinic, Villaroel 170, Barcelona 08036, Spain.
Best Pract Res Clin Gastroenterol. 2007;21(1):55-75. doi: 10.1016/j.bpg.2006.07.012.
The natural course of patients with cirrhosis is frequently complicated by the accumulation of fluid in the peritoneal or pleural cavities and interstitial tissue. Functional renal abnormalities that occur as a consequence of decreased effective arterial blood volume are responsible for fluid accumulation in the form of ascites and hepatic hydrothorax. Ascites is the most common complication of cirrhosis and poses an increased risk for infections, renal failure and mortality. Patients have a poor prognosis and it is estimated that nearly half will die in approximately 2 years without liver transplantation. Hepatic hydrothorax is defined as a pleural effusion greater than 500 mL (mostly right-sided) in patients with cirrhosis without cardiopulmonary disease; the estimated prevalence is approximately 5-10%. Liver transplantation is the most definitive cure for both conditions in those patients that are suitable candidates. However, the mainstay of therapy for minimizing fluid accumulation in both conditions includes sodium restriction and administration of diuretics. This article reviews the most current concepts of pathogenesis, clinical findings, diagnosis, and treatment of these complications of cirrhosis.
肝硬化患者的自然病程常因腹腔、胸腔和间质组织中液体的积聚而复杂化。有效动脉血容量减少导致的功能性肾脏异常是腹水和肝性胸水形式的液体积聚的原因。腹水是肝硬化最常见的并发症,会增加感染、肾衰竭和死亡的风险。患者预后较差,据估计,近一半患者在无肝移植的情况下约2年内会死亡。肝性胸水定义为肝硬化且无心肺疾病患者胸腔积液超过500 mL(大多为右侧);估计患病率约为5%-10%。肝移植是适合的患者治疗这两种疾病的最确切方法。然而,在这两种情况下,尽量减少液体积聚的主要治疗方法包括限钠和使用利尿剂。本文综述了肝硬化这些并发症的发病机制、临床表现、诊断和治疗的最新概念。